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ABSTRACT
In order to decrease the morbidity and mortality caused by seasonal influenza outbreaks, several hundred million vaccine doses 
are produced worldwide each year. The predominant substrate for the production of the influenza vaccine today is fertilized hen’s 
eggs. The substitution of the technology based on living organisms by the cell culture-based process offers many advantages, 
including easier scalability and reduced dependence on the availability of eggs. The African green monkey kidney and Madin Darby 
canine kidney cell lines support the efficient growth of influenza viruses of different subtypes and, therefore, are considered to be 
the two most promising alternative substrates for the production of the human influenza vaccine. 
However, the pH of endosomes in both of these cell lines is higher than the pH essential for triggering a conformational 
change of the hemagglutinin (HA) of human influenza viruses, which enables the viral-cellular membrane fusion. This mismatch 
gives rise to mutations in the HA that lead to an increase of the optimum pH of HA conformational change. As of a result of these 
mismatches, the HA, and consequently the whole virus, has reduced stability to low pH and elevated temperatures. The production 
of a vaccine from less stable virus will lead to an elevated HA content in the low pH conformation that can affect the safety, 
potency, infectivity, and protective efficacy of the final inactivated and live attenuated influenza vaccines.
The main limitations of the cell line-based influenza vaccine technology and the possibilities to preserve the viral stability over 
the course of influenza vaccine production are discussed in the review.
INTRODUCTION
According to data from the World Health Organization 
(WHO), seasonal influenza epidemics cause 250,000 
to 500,000 deaths worldwide every year. Vaccination 
remains the primary measure to prevent the spread of 
this virus and to reduce the morbidity and mortality 
caused by influenza disease. 
The influenza virus belongs to the family 
Orthomyxoviridae that comprises five genera: influenza 
A, B, C, Thogotovirus, and Isavirus. Influenza A and 
B viruses are the only types that infect humans. The 
host antibodies are generated to the influenza virus 
surface glycoproteins: hemagglutinin (HA or H) and 
neuraminidase (NA or N). These proteins are responsible 
for the virus attachment to the target cells and subsequent 
release of new virus particles. To date, 18  variants of 
HAs and 11 variants of NAs are known for the influenza 
A  virus. The combination of different HAs and NAs in 
virus defines the influenza A virus subtype. Only the 
viruses of three subtypes, i.e. A(H1N1), A(H2N2), and 
A(H3N2), have been circulating in the human population 
that have caused outbreaks and pandemics. There are 
no known subtypes for the influenza B virus strains, 
although two antigenically different lineages have been 
identified, B/Victoria and B/Yamagata. 
The WHO performs permanent surveillance and 
control of new influenza viruses based on the data 
provided by the National Influenza Centers. The National 
Centers isolate the viruses from infected humans and 
characterize them in terms of their antigenic properties 
and the HA and NA primary structure. The isolation is 
performed in fertilized hen’s eggs or in Madin Darby 
canine kidney (MDCK) cell line. Two times per year, 
the WHO selects the most dominating strains and 
recommends them for the vaccine composition for 
Northern and Southern hemisphere, respectively (http://
www.who.int/influenza/en/). The vaccine composition 
includes two strains of influenza A (H3N2 and H1N1) 
and one strain of B virus for the production of trivalent 
preparation. The high growth seed viruses of influenza A 
are generated by the genetic reassortment of the H1N1 
and H3N2 viruses provided by the WHO Collaborative 
Centers with egg-adapted virus A/Puerto Rico/8/34 
(H1N1) (PR8). Influenza B strains are used without any 
reassortment. All seed viruses are then distributed to the 
manufacturers. It is important to notice that only egg-
isolated virus strains are allowed for use in the vaccine 
production because of the established safety parameters 
for this substrate.
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Reports about the sporadic infections of humans 
with low pathogenic (H9N2, H7N2, H7N3) and highly 
pathogenic (H5N1, H7N3, H7N7, and H7N9) avian 
influenza viruses (LPAIVs and HPAIVs, respectively) are 
constantly being published [1-4]. The wild aquatic birds 
are the main source of LPAIVs. These viruses replicate 
predominantly in the intestinal tract of birds and induce 
asymptomatic infection [5]. Sporadically, LPAIVs infect 
domestic animals and poultry, and can infect humans 
working on the animal and poultry farms causing the 
symptomatic disease. The disease induced by HPAIVs is 
more severe. These viruses infect wild birds as well as 
poultry and induce infection with a mortality rate close to 
100%. The reassortment of any avian virus with a human 
strain can result in the emergence of the virus with new 
antigenic proteins. Such a virus would have pandemic 
potential since the human population lacks immunity to 
the avian HA and NA proteins and, consequently, a pre-
pandemic vaccine should be produced in this case.
The vast majority (approx. 500 million doses) of 
all the existing vaccines are produced in hen’s eggs – 
an old production system developed in the 1950s [6]. 
The production of the influenza vaccine in eggs is a 
cumbersome and time-consuming process. The duration 
of the whole process is about 6 months. The eggs for 
vaccine manufacture must be free of any pathogens 
(specific pathogen free, SPF) and should be ordered in 
advance to insure the continuous process. The estimated 
current capacity of all vaccine producing companies is 
1.42 billion doses per year, which is not enough to supply 
the world’s population in the case of a pandemic threat 
[6]. Substitution of the egg-based vaccine production 
technology by the process based on continuous cell lines 
offers many advantages including easier scalability and 
reduced dependence on eggs availability. Several cell 
lines, such as Vero, MDCK, human embryonic retinal 
(PER.C6), and human embryonic kidney (HEK293) cells, 
are considered as candidates for vaccine production. 
The Vero and MDCK are the two most developed to date 
cell lines recommended by the WHO as safe substrates 
for the production of human influenza vaccine. Vero 
cell line is widely used for the production of Inactivated 
Polio Vaccine (IPV), rotavirus (RotaTeq and Rotarix) and 
smallpox (ACAM2000) vaccines. Baxter International Inc. 
developed the technology for the production of influenza 
vaccine in Vero cells grown on Cytodex microcarriers. 
Trivalent Vero-derived influenza vaccine against 
seasonal influenza, Preflucel, was licensed in European 
Union (EU) in 2010. The pandemic vaccine Celvapan© 
against H1N1pdm09 virus and pre-pandemic vaccine 
Vepacel against H5N1 virus were also licensed in EU [7]. 
However, in 2011, 300,000  doses of Preflucel vaccine 
were withdrawn from the market because of a high 
percentage of side effects noticed after the vaccination. 
Sanofi Pasteur had undertaken an attempt to develop 
the production of the inactivated influenza vaccine in 
PER.C6 cells, but this project was discontinued. First 
influenza MDCK-derived vaccine Influvac was licensed 
in the Netherlands by Solvay Biologicals as a split virus 
preparation produced in cells cultivated in Cytodex 
microcarriers [8]. Nevertheless, after the acquisition of the 
Solvay Biologicals by Abbott, the production of Influvac 
vaccine was discontinued. The attempts undertaken by 
MedImmune and Nobilon to develop the production 
of the two live attenuated influenza (LAI) vaccines in 
MDCK cells were also stopped. The only one MDCK-
derived vaccine approved in EU [9] and the US today is 
Optaflu/Flucelvax (Novartis) – the trivalent subunit 
vaccine against seasonal influenza. In addition, Protein 
Sciences [10] licensed in the US the first recombinant 
trivalent influenza vaccine FluBlok produced in insect 
expresSF cells using a baculovirus expression system. 
The main limitations of the cell line-based technology 
for influenza vaccine production are discussed in this 
review.
Differences between human and avian influenza 
viruses
The binding affinity of virus HA protein to the cells of 
different species is one of the parameters that defines 
the species barrier for influenza viruses. The influenza 
viruses initiate the infection via attachment to the ciliated 
epithelial cells in the upper respiratory tract (URT). The 
HAs of human influenza viruses recognize and bind to 
oligosaccharide chains terminated with the sialic acid-
α2,6-galactose (SAα2,6Gal), which are prevalent on the 
human upper respiratory tract epithelial cells [11]. The 
avian influenza viruses bind to the SAα2,3Gal-terminated 
glycans that dominate on the surface of avian epithelial 
tissues [12]. Cells expressing the SAα2,3Gal-saccharides 
are known to be present in human bronchial epithelium 
and dominate in human lungs. Therefore, the avian 
influenza viruses can induce the disease in humans if the 
virus reaches lungs of the exposed person, for example, 
upon the close contact with infected bird.
One of the innate mechanisms of defense in mammals 
is the acidification of the mucosal surfaces of the nasal 
passageways in response to irritation or inflammation. 
The degree of acidification of these surfaces in mammals 
varies depending on the distribution and activity of the 
submucosal glands. The pH of the human passageway 
has a range from 5.2 to 8.0 [13-18]. Therefore, the 
efficient infection of human URT cells requires a certain 
level of virus stability to acidic pH. The acidic pH triggers 
the HA irreversible conformational change to the low 
pH form. This HA structural change happens in the 
endosome upon acidification and enables the fusion of 
the endosomal and viral membranes in order to release 
the viral genome to the cell cytoplasm. The pH threshold 
necessary for the HA conformational change is called the 
pH of fusion. The HAs of human and LPAIVs are known 
to change the conformation at the pH range from 5.1 to 
5.4 [19, 20]. The HAs of HPAIVs are characterized by an 
elevated pH of fusion (from 5.6 to 6.0) [20] and, therefore, 
these viruses are much less stable to the acidic pH than 
LPAIVs and seasonal influenza viruses [21].
The essential prerequisite for influenza virus 
replication is the HA cleavage to HA1 and HA2 subunits 
by cell proteases that is necessary for release the fusion 
peptide. The HA of the human and LPAI viruses contains 
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a single arginine (-R-) cleavage site that is cleaved by 
the trypsin-like serine proteases present in the human 
airways [22]. The HAs of HPAIVs contain the polybasic 
cleavage site (e.g. R-S-S-R or R-S-R-R) that is cleaved 
by intracellular furin-like serine proteases expressed in 
different tissues [23]. This feature enables virus spreading 
to different organs and the induction of systemic 
infection. Therefore, the HPAIVs are highly virulent for 
humans and cause influenza disease with a mortality rate 
exceeding 50%. All of these differences between human 
and avian influenza viruses have to be taken into account 
when developing the vaccine production technology.
Virus adaptation passages and their consequences
As it was already mentioned, the primary influenza 
viruses are isolated in the fertilized hen’s eggs. The cells 
of the amniotic and chorioallantoic membranes of the egg 
are the main target cells for influenza virus replication. 
These cells express both types of sialylated glycans, but 
predominantly with SAα2,3Gal linkage. The shortage of 
the human-like receptors in eggs is the first barrier for the 
effective replication of some human influenza isolates. 
Thus, the insufficient growth of virus A/Fujian/411/2002 
(H3N2) induced the delayed vaccine production in the 
season of 2003-2004 [24]. For the same reason in 2008, 
it was necessary to substitute the poorly growing virus 
A/Brisbane/10/2007 (H3N2) by the A/Uruguay/716/2007 
(H3N2) virus. In order to overcome this limitation, 
the primary isolates are usually subjected to several 
consecutive passages in eggs. The other approach is to 
perform the reassortment process with PR8 virus in the 
primary chicken embryo kidney cells instead of eggs. 
Both ways are associated with the emergence of the 
adaptation mutations in the HA protein that can change 
the receptor-binding and antigenic properties, or change 
the pH of HA fusion [25-27].
Earlier, we investigated the emergence of HA 
mutations upon the isolation of human influenza viruses 
from clinical material in eggs, as well as in the MDCK 
and Vero cell lines [28]. We found that the isolation of 
influenza A viruses in eggs was always accompanied by 
HA mutations. The amino acid substitutions found for 
the H1N1 viruses (225Asp→Gly, 226Gln→Arg) or for the 
H3N2 viruses (194Leu→Ile, 220Arg→Ser) were located 
near the HA receptor-binding site (RBS), and were 
associated with its specificity [29]. One (220Arg→Ser) or 
two (133Asn→Asp, 218Gly→Glu) substitutions located 
near the HA RBS were found in H3N2 viruses isolated 
in the MDCK cells as opposed to the Vero cells. These 
mutations were associated with the glycosylation pattern 
of the MDCK cells [28]. The sequence of the HA1 subunit 
of H1N1 viruses isolated in both Vero and MDCK cells 
was identical to that of the human virus present in swab. 
However, mutations in the HA2 fusion peptide were often 
identified for H1N1 viruses (unpublished data).
The Vero and MDCK continuous cell lines are 
known to have an equal amount of cells containing 
the saccharides with both types of sialic acid linkages 
(SAα2,3Gal as well as SAα2,6Gal) on the surface [30]. 
Most of the human influenza primary isolates easily grow 
in MDCK cells, while their growth in Vero cells is less 
efficient. The authors of several publications have shown 
[25, 31] that the adaptation of influenza viruses to the 
growth in MDCK and Vero cell lines induces mutations 
that increase the pH of fusion of the influenza virus HA. 
According to the experimental data, the endosomal pH in 
MDCK cells is around 6.4 and reaches even higher values 
in Vero cells [31, 32]. The endosomal pH in the chicken 
embryo fibroblasts (CEF) is around 6.4, however, there 
is no data available on the endosomal pH of the cells in 
the chorioallantoic or amniotic membranes [32]. All the 
above mentioned data lead to the conclusion that the 
relatively high endosomal pH might explain the selection 
of mutants with an increased pH of HA fusion post 
adaptation to the growth in MDCK and Vero cell lines.
Thus, none of the studied substrates are ideal for 
the cultivation of human influenza viruses. In order to 
assess the consequences of virus adaptation to various 
substrates, we performed 5 consecutive passages of H1N1, 
H3N2, and influenza B viruses in eggs as well as in the 
MDCK and Vero cell lines and compared the properties 
of obtained viruses [33]. The egg-derived seed viruses 
recommended for the vaccine production were selected 
as the starting material. Previously, we demonstrated 
[34] that HA mutations that increase the pH of HA fusion 
lead to decreased stability of the virus to the low pH and 
elevated temperatures. These vaccine candidates showed 
the decreased immunogenicity upon the intranasal 
immunization of ferrets. Therefore, the pH of HA fusion 
and virus stability were the main parameters assessed in 
this study. 
According to the obtained data, no mutations were 
revealed after 5 passages of influenza B strain in any of 
these substrates. Five passages of A/Brisbane/59/2007 
(H1N1) and A/Brisbane/10/2007 (H3N2) viruses in eggs 
also did not induce any changes in HA. On the other 
hand, 5 passages of A/Brisbane/59/2007 (H1N1) in Vero 
cells, as opposed to the MDCK cells, led to mutations that 
increased the pH of HA fusion by 0.4 units. This change 
was associated with HA1 mutation 190Asn→Val and HA2 
stalk mutation 50Asn→Lys. The resultant virus became 
more sensitive to the acidic pH and elevated temperatures. 
The passages of A/Brisbane/10/2007 (H3N2) virus in both 
MDCK and Vero cells induced the enhancement of the pH 
of HA fusion by 0.1 unit (HA2 mutation 160Asp→Glu) 
that was associated with decreased stability to acidic pH 
and elevated temperatures. It is necessary to mention 
that the pH of HA fusion of initial egg-derived virus A/
Brisbane/10/2007 was 6.0. This value is 0.4 units higher 
than that known for the human influenza viruses and 
particularly for the antigenically similar human isolate 
A/Nizhniy Novgorod/ 668/08. One can assume that the 
enhancement of pH of fusion of A/Brisbane/10/2007 
virus HA happened upon the adaptation passages in 
eggs. Additional passages of this virus in both cell lines 
led to a further increase of the pH of HA fusion and to a 
decrease in its stability. For all of the obtained mutants, 
the increased pH threshold of HA conformational change 
was associated with reduced virus stability to acidic pH 
and elevated temperatures. 
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Furthermore, we showed that the concentrated 
purified preparation made from the less stable virus 
mutant contained about 50% less HA than the analogous 
preparation from the more stable virus according to the 
single radial immunodiffusion (SRID) assay. This assay 
measures the amount of HA molecules present in the 
vaccine in the native conformation [35]. 
The obtained data show that the passages of human 
influenza viruses in eggs as well as in the MDCK and Vero 
cell lines induce mutations that increase the pH of HA 
fusion, which in turn impair the virus stability toward low 
pH and elevated temperatures. The mutations related 
to this change were identified in various HA regions, 
including the receptor-binding domain [36], interface 
between the HA1 and HA2 subunits [37-39], the coiled-
coil regions of the HA2 subunit [37, 40, 41], and the fusion 
peptide pocket [40, 42]. However, it seems that passages 
in eggs impair the virus stability less dramatically than 
the analogous passages in both cell lines. The effect of 
mutations decreasing virus stability on the quality of 
influenza vaccines is discussed below.
Effect of the influenza virus stability on the quality 
of inactivated vaccines 
The inactivated influenza vaccines are available as 
a whole virion, split or subunit preparations that 
include 3 components (15 μg of each) and are designed 
for intramuscular or subcutaneous administration. 
The efficiency of the inactivated influenza vaccine is 
determined by the amount of antibodies induced to the 
native HA trimeric structure, which is measured by the 
hemagglutination inhibition assay (HAI). 
The HA of influenza virus with increased pH of 
fusion is converted to the low pH form much easier. This 
conformational change is irreversible and happens not 
only at acidic pH, but also at elevated temperatures or 
upon exposure to the denaturing reagents [43]. Depending 
on the vaccine type, the downstream production 
process might include a number of steps, such as virus 
inactivation, concentration by ultracentrifugation, 
purification by chromatography, precipitation, sucrose-
gradient centrifugation, chemical disruption, and sterile 
filtration. All of these steps can trigger the conversion 
of less stable HA to the low pH form. The HA in the low 
pH form expresses the hydrophobic domains, which 
are prone to form aggregates. The presence of viral 
aggregates in the vaccine can induce the severe adverse 
effects. Thus, the emergence of the new oculo-respiratory 
syndrome was detected in 2000-2001 season in adults 
after immunization with the vaccine that contained a 
high amount of aggregated unsplit virus particles [44, 
45]. Viruses that contain the structurally modified HAs 
are known to become more sensitive to the cleavage with 
proteolytic enzymes [46]. In addition, the low pH form of 
HA expresses the epitopes that are hidden in the native 
HA conformation. These epitopes induce cross-reactive 
antibodies with less neutralizing potential [47, 48].
Similar problems were observed in the course of 
production of the pre-pandemic vaccines from the H5N1 
HPAIVs. The inactivated vaccines produced from these 
viruses by conventional methods were found to have 
decreased HA content and immunogenicity compared to 
the vaccines against seasonal influenza viruses produced 
by the same methods [49, 50]. The antibodies induced 
post immunization poorly reacted in the HAI test [51]. 
In order to reach the protective level of antibodies post 
immunization with the H5N1 vaccine it was necessary to 
increase the vaccine dose up to 45-90 μg or to add the 
adjuvant. At the same time, in some studies the better 
heterosubtypic cross-protection was observed after 
immunization with H5N1 vaccines [52].
We hypothesized that the high pH of HA fusion 
known for the HA of HPAIVs is the main factor affecting 
the properties of vaccines produced from these viruses. 
In order to prove that, we introduced the mutation 
58Lys→Ile, which is known to decrease the pH of HA 
fusion, in the HA2 subunit of A/Kurgan/05/2005 (H5N1) 
virus [53]. Two similar 6/2 reassortants, one containing 
the original HA and the other with the mutant HA, in 
combination with NA gene from A/Kurgan/05/2005 and 
all the other genes from the PR8 virus were constructed. 
The reassortant with the mutant HA was characterized by 
a decreased pH of HA fusion by 0.3 units [54] and increased 
stability toward an acidic pH and elevated temperatures 
compared to the reassortant with the original HA protein. 
Two inactivated whole virion vaccine preparations were 
produced using these reassortants and their properties 
were compared. We have shown that vaccine preparation 
from the virus with the mutant HA was more stable to 
freezing-thawing stress and more resistant to trypsin 
digestion. The HA content measured by the SRID test 
for this vaccine preparation was higher than that for the 
vaccine made from the virus with the original HA. 
Therefore, the production of the seasonal and pre-
pandemic inactivated influenza vaccines from viruses 
with reduced stability could lead to decreased vaccine 
quality.
Effect of influenza virus stability on the quality 
of live attenuated vaccines 
Two LAI vaccines are approved for human use. The first 
vaccine is licensed in the US and Europe (FluMist®, 
MedImmune, USA) [55], while the second vaccine is 
licensed in Russia [56]. Both vaccines contain the cold 
adapted (CA) attenuated vaccine strains (6/2 reassortants) 
produced in eggs and are designed for intranasal 
application. It is known that the immunogenicity of a live 
vaccine correlates with the productive replication of the 
vaccine strains in the URT of humans [57].
The analysis of the clinical data shows that the 
immune response induced by both licensed vaccines is 
inconsistent. Thus, the pre-pandemic vaccine produced 
from the virus of H2N2 subtype (FluMist®) showed 
the restricted virus replication in the URT (24%) and 
immune response in only 24% of participants [58]. The 
vaccine strain used in this study was the master strain 
A/Ann Arbor/6/1960 (H2N2) that is used as a backbone 
for the seasonal vaccine strains. At the same time, 
the Russian pre-pandemic vaccine of H2N2 subtype, 
which contains the reassortant of the master stain 
 Volume 4     Number 1     2017 5 mir-journal.org 
Cell-based influenza vaccines
A/Leningrad/134/17/1957 CA with the A/California/1/1966 
(H2N2) virus, showed a high replication rate in the URT 
of volunteers (78.6%) and a high number of responders 
(92.6%) [57]. The analysis of the origin of both vaccine 
strains revealed that the virus A/Ann Arbor/6/1960 CA 
was isolated and attenuated by serial passages in the 
primary chicken kidney cells and had decreased stability 
to the acidic pH compared to the original wild type 
strain [59]. The virus strain used in the Russian vaccine 
preparation was obtained by classical reassortment 
in eggs. The surface antigens of this vaccine strain 
were inherited from the epidemic egg-derived isolate 
A/California/1/1966 (H2N2) [60]. Based on our results 
discussed herein above, we can assume that the decreased 
stability of A/Ann Arbor/6/1960 CA virus is one of the 
reasons leading to its restricted immunogenicity.
Another reason for the low immunogenicity of 
the vaccine strains of the LAI vaccine could be the 
incompatibility of the HA and M genes originated from 
different strains. O’Donnell et al. [61] showed that 6/2 
reassortants of A/Ann Arbor/6/1960 CA (H2N2) master 
strain with viruses of H1N1, H3N2, H2N2, H6N1, H7N3, 
H9N2, and H5N1 subtypes have an elevated pH of HA 
fusion and decreased stability to low pH and elevated 
temperatures compared to the corresponding epidemic 
viruses. Clinical trials performed with some of 6/2 
reassortants showed their restricted replication in the 
respiratory tract of seronegative adult volunteers [58, 
62, 63]. The authors of these papers have found that 
the decreased stability of the studied reassortants is 
connected with the nature of the M gene of A/Ann 
Arbor/6/1960 CA master strain, but the exact mechanism 
of this phenomenon was not discussed.
One of the proteins coded by M gene is the M2 
that is known to have the ion channel activity. It was 
shown that the M2 protein plays a major role in the 
preservation of the HA native conformation, preventing 
the premature HA conformational change to the low pH 
form during the virus transport to the cell surface [64]. 
Earlier we demonstrated [65] that the M2 protein of 
the virus A/Singapore/1/1957 CA (H2N2) has lower ion 
channel activity than the M2 of A/Switzerland/5389/1995 
(H1N1). The 6/2 and 5/3 reassortants that contain the 
HA and NA or HA, NA and M genes, respectively, from 
the A/Switzerland/5389/1995(H1N1) virus and all the 
other genes from the A/Singapore/1/1957 CA were 
constructed. The intranasal immunization of mice 
with these reassortants showed the clear difference 
in the amount of antibodies directed to the HA1 and 
HA2 subunits. Therefore, the 6/2 reassortant induced 
1.7  times more antibodies to the HA2 subunit than to 
HA1. At the same time, the HA2/HA1 ratio of antibodies 
induced by 5/3 reassortant was almost similar to that 
induced by A/Switzerland/5389/1995 virus (1.1 and 1.0, 
respectively). These results indicate that the M2 protein 
of A/Singapore/1/1957 CA, which has low ion channel 
activity, did not prevent the premature conformational 
change of the A/Switzerland/5389/1995 HA protein to 
the low pH form during transport to the cell membrane. 
A similar mechanism can contribute to the premature 
conformational change of HA in 6/2 reassortants 
produced from the A/Ann Arbor/6/1960 CA (H2N2) strain 
and consequently cause their decreased stability.
The attempts to vaccinate humans with pre-pandemic 
H5 live influenza vaccines gave the contradictory results. 
The vaccine strains containing the surface antigens of 
HPAIVs A/Vietnam/1203/2004 or A/Hong Kong/213/2003 
of H5N1 subtype produced using the A/Ann Arbor/6/1960 
CA strain (MedImmune) failed to replicate in the human 
nasal mucosa and to induce a reasonable immune response 
[66]. At the same time, the vaccine strain containing the 
HA of the LPAIV A/Potsdam/1402-6/1986 (H5N2) and all 
other genes from the A/Leningrad/134/17/1957CA virus 
replicated efficiently in the URT of humans (up to 10 days) 
and caused the reasonable systemic and local immune 
response [67]. This contradiction could be explained 
by the different HA stability of the corresponding 
reassortants depending from which virus (HPAIVs or 
LPAIV) the HA gene was inherited.
In order to prove this hypothesis we introduced the 
mutation 58Lys→Ile, which is known to decrease the pH 
of HA fusion, in the HA2 of HPAIV A/Vietnam/1203/2004 
(H5N1). Then two analogous 6/2 reassortant vaccine 
candidates – one with the mutant and the other with 
the original HA gene – were constructed based on PR8 
virus. The attenuation of these viruses was provided 
by deletion of the NS1 mRNA open reading frame [21]. 
We have demonstrated that the virus with mutant 
HA was characterized by a decreased pH of HA fusion 
and enhanced stability toward low pH and elevated 
temperatures compared to the analogous virus with 
original HA sequence. Both viruses were used for the 
intranasal immunization of mice. The immunization 
with a more stable virus resulted in increased virus 
replication in the nasal mucosa, trachea, and lungs of 
mice as well as induced enhanced humoral and local 
immunity compared to the virus bearing the original HA. 
Therefore, the HA stability of the LAI vaccine 
reassortants to the low pH and elevated temperatures 
is crucial for their effective replication in the URT of 
mammals that consequently could affect the vaccine 
efficacy. 
CONCLUSION
The cultivation of the human influenza viruses in 
continuous cell lines such as MDCK and VERO often 
leads to the emergence of HA mutations that increase the 
pH of HA fusion and dramatically decrease the stability 
of HA protein, and consequently the whole virus, to 
different physical and chemical factors. These viruses 
are much more sensitive to the procedures of vaccine 
manufacturing. As a result, the vaccine virions contain a 
bigger portion of HA proteins in the low pH form, which 
can affect the safety, potency, infectivity, and protective 
efficacy of the final inactivated and live attenuated 
influenza vaccines. 
We found a set of conditions that should be met in 
order to keep the optimal quality of vaccines produced 
in the cell lines. First, it is necessary to maintain the 
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HA sequence in the vaccine strain as close as possible 
to that of the original human virus isolate. In order to 
accomplish this, the HA and NA genes primary structure 
of the virus recommended for vaccine composition 
should be determined before any isolation passages. The 
construction of vaccine reassortants by reverse genetics 
methods allows for the cloning of the HA sequence 
identical to that of the virus present in the human swab, 
and for the rescue of the virus without any adaptation 
mutations. The next important goal is to prevent the 
emergence of HA mutations associated with increased 
pH of HA fusion during the vaccine production. We 
have demonstrated that the propagation of viruses at 
acidified conditions in Vero cell line helps to preserve 
the original HA primary structure and the virus stability 
[33]. Another possibility to prevent the emergence of 
adaptation mutations that increase the pH of HA fusion 
is to cultivate the virus in the presence of Amphotericin 
B promoting fusion of viral and cellular membranes [68]. 
Moreover, the new cell lines that support the effective 
replication of the human influenza viruses and have low 
endosomal pH are promising candidates for influenza 
vaccine production. Cultured mouse heart cells could be 
considered as an example, since they have more acidic 
endosomes (pH 5.5) than cultured mouse kidney cells 
(pH 6.0) [69]. 
In conclusion, all attempts to develop and produce 
new cell culture-based influenza vaccines, without taking 
into account HA mutations leading to an increase of the 
pH of HA conformational change, are doomed to failure. 
It is obviously that more research in both academia and 
industry is necessary to develop the new cell-based 
technologies for the influenza vaccine production.
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